ACTA PHARMACOLOGICA SINICA

Scope & Guideline

Elevating Research in Pharmacological Sciences

Introduction

Delve into the academic richness of ACTA PHARMACOLOGICA SINICA with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1671-4083
PublisherNATURE PUBL GROUP
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1980 to 2024
AbbreviationACTA PHARMACOL SIN / Acta Pharmacol. Sin.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressMACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

ACTA PHARMACOLOGICA SINICA focuses on innovative research in pharmacology, emphasizing the exploration of therapeutic agents, drug mechanisms, and the biological effects of pharmaceuticals. The journal serves as a platform for disseminating high-quality studies that contribute to the understanding of drug action and the development of new therapeutic strategies.
  1. Pharmacodynamics and Pharmacokinetics:
    Research on the mechanisms of drug action, including absorption, distribution, metabolism, and excretion of drugs, to understand their therapeutic effects and side effects.
  2. Molecular Pharmacology:
    Investigations into the molecular mechanisms underlying drug interactions with biological systems, contributing to the identification of new drug targets.
  3. Translational Medicine:
    Studies that bridge the gap between laboratory research and clinical application, focusing on how laboratory findings can inform clinical practice and improve patient outcomes.
  4. Neuropharmacology:
    Research dedicated to understanding how drugs affect the nervous system, including studies on neurodegenerative diseases, pain management, and psychiatric disorders.
  5. Natural Products and Traditional Medicines:
    Exploration of pharmacological properties of natural compounds and traditional medicines, including their potential therapeutic applications and mechanisms of action.
  6. Cancer Pharmacology:
    Research focused on the mechanisms of action of anti-cancer agents, drug resistance, and the development of novel therapeutic strategies for cancer treatment.
  7. Immunopharmacology:
    Studies examining the interplay between pharmacological agents and the immune system, including the development of immunotherapies for various diseases.
Emerging themes within ACTA PHARMACOLOGICA SINICA reflect the journal's responsiveness to current trends in pharmacological research. The following areas have gained traction, indicating a shift in research priorities and interests among authors.
  1. Ferroptosis and Cell Death Mechanisms:
    Research focusing on ferroptosis, a form of regulated cell death, has surged, particularly in relation to cancer treatment and neurodegenerative disease mechanisms.
  2. Microbiome and Drug Interactions:
    Studies exploring the relationship between gut microbiota and drug metabolism or therapeutic effects are increasingly prominent, highlighting the importance of microbiome research in pharmacology.
  3. Targeted and Personalized Medicine:
    There is a growing emphasis on targeted therapies and personalized medicine approaches, particularly in oncology, reflecting advances in understanding individual patient responses to treatment.
  4. Nanomedicine and Drug Delivery Systems:
    Innovative drug delivery systems utilizing nanotechnology are gaining attention, particularly for their potential to enhance therapeutic efficacy and reduce side effects.
  5. Immunotherapy Approaches:
    Research into immunotherapeutic strategies, especially for cancer treatment, is on the rise, reflecting the success of immune checkpoint inhibitors and CAR-T cell therapies.
  6. Biomarker Discovery and Application:
    The identification and application of biomarkers for predicting drug response and disease progression are trending, emphasizing the integration of biomarkers in clinical pharmacology.
  7. Neuroinflammation and CNS Disorders:
    Increased research on neuroinflammation and its role in central nervous system disorders is emerging, particularly in the context of developing new therapeutic strategies.

Declining or Waning

As the field of pharmacology evolves, certain themes within ACTA PHARMACOLOGICA SINICA have shown a decline in publication frequency. This section highlights areas that appear to be waning in prominence, suggesting a shift in research focus among authors.
  1. Basic Pharmacological Studies:
    There has been a noticeable decline in purely basic pharmacological studies that do not translate to clinical relevance, as researchers increasingly prioritize translational and applied research.
  2. Pharmacogenetics:
    While pharmacogenetics remains important, the frequency of studies specifically targeting genetic determinants of drug response has decreased, possibly due to the rising focus on broader systems biology approaches.
  3. Drug Development Process:
    Research specifically detailing the early drug development phases has seen reduced coverage, as more studies focus on late-stage clinical trials and real-world applications.
  4. Toxicology Studies:
    Studies solely focused on the toxicological aspects of drugs without a clear therapeutic angle are less frequently published, reflecting a shift towards understanding therapeutic windows and drug safety in clinical contexts.

Similar Journals

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Connecting researchers and practitioners in pharmacology.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

INDIAN JOURNAL OF PHARMACOLOGY

Fostering excellence in pharmacology through rigorous inquiry.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

CHEMICO-BIOLOGICAL INTERACTIONS

Advancing Understanding in Pharmacology and Toxicology
Publisher: ELSEVIER IRELAND LTDISSN: 0009-2797Frequency: 18 issues/year

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Fostering Excellence in Biomedical and Pharmaceutical Discourse
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

PHARMACEUTICAL BIOLOGY

Advancing the Frontiers of Pharmaceutical Science and Biology
Publisher: TAYLOR & FRANCIS LTDISSN: 1388-0209Frequency: 1 issue/year

PHARMACEUTICAL BIOLOGY, published by Taylor & Francis Ltd, is a prominent open-access journal that has been a cornerstone of research in the life sciences since its convergence in 1961. With a strong focus on Complementary and Alternative Medicine, Pharmaceutical Science, and Drug Discovery, this journal is dedicated to disseminating groundbreaking research that intersects pharmaceuticals and biology. Acknowledged for its rigorous peer-review process, it holds a prestigious Q1 ranking in Pharmaceutical Science and exemplifies the commitment to quality and impact in the field, boasting an impressive Scopus rank of #14/105 in the complementary and alternative medicine category. Researchers keen on advancing their knowledge in these fields will find PHARMACEUTICAL BIOLOGY an invaluable resource, offering accessibility since its shift to open access in 2017. This journal presents a platform for innovative studies that contribute to the evolving understanding of pharmaceutical applications and biological interactions, serving as an essential hub for researchers, professionals, and students alike.

ANTI-CANCER DRUGS

Exploring New Horizons in Anti-Cancer Treatments
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Current Molecular Pharmacology

Showcasing Transformative Discoveries in Molecular Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

JOURNAL OF PHARMACY AND PHARMACOLOGY

Advancing pharmaceutical knowledge for a healthier tomorrow.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

BRITISH JOURNAL OF PHARMACOLOGY

Elevating research standards in the field of pharmacology.
Publisher: WILEYISSN: 0007-1188Frequency: 24 issues/year

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Advances in Pharmacological and Pharmaceutical Sciences

Pioneering Insights in Toxicology and Drug Development.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.